About Our Advisory Council
The Neoteryx Advisory Council consists of influential leaders in their fields, those who have been major contributors in the development and spread of microsampling technology. They are well positioned to help shape its present and guide its future.
Thierry Dervieux, Ph.D
Chief Scientific Officer & Medical Lab Director at Exagen Diagnostics
Chief Scientific Officer and Medical Lab Director of Exagen Diagnostics since Oct 2010. Dr. Dervieux has over 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry.
Thierry Dervieux, Ph.D. has served as the Chief Scientific Officer and Medical Laboratory Director of Exagen Diagnostics since October 2010.
Dr. Dervieux has over 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Prior to joining Exagen, Dr. Dervieux was Vice President of Research and Development with Cypress Bioscience, Inc., a pharmaceutical company with a focus on drugs to treat central nervous system disorders, where he developed our current portfolio in the rheumatology space from 2008 to October 2010.
He previously served as Senior Director Research and Development with Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, until its acquisition by Cypress Bioscience.
Prior to that, he served as Principal Scientist and Director of Research and Development at Prometheus Laboratories.
Dr. Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, and diagnostic immunology. Dr. Dervieux holds Pharm.D. and Ph.D. degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from the University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children™'s Research Hospital in Memphis, Tennessee.
Philip Lorenzi, PhD,
Director of Proteomics and
Metabolomics at MD Anderson
Head of the laboratory at John Weinstein, MD, PhD, in the Department of Bioinformatics & Computational Biology and is also Co-Director of the Proteomics and Metabolomics Core Facility at The University of Texas MD Anderson Cancer Center.
Philip Lorenzi, PhD, heads the laboratory of John Weinstein, MD, PhD, in the Department of Bioinformatics & Computational Biology and is also Co-Director of the Proteomics and Metabolomics Core Facility at The University of Texas MD Anderson Cancer Center.
His graduate studies in Pharmaceutical Sciences at The University of Michigan focused on pharmacokinetics, drug metabolism, and prodrug synthesis. His postdoctoral training at the U.S. National Cancer Institute (NCI) focused on using functional genomics and metabolomics to elucidate predictive biomarkers of drug response.
While at the NCI, he also earned a Pharmacology Research Associate Fellowship and an NCI Director’s Innovation Award for developing a new approach for identifying synergistic drug combinations, which remains an area of interest.
He spearheaded the addition of metabolomics capabilities to form the Proteomics and Metabolomics Core Facility at MD Anderson, developing a pipeline that offers assisted or full-service experimental support for exploratory, preclinical, and clinical studies involving proteomics and metabolomics. Using mass spectrometry as a core technology, the highly interdisciplinary team (including analytical chemists, molecular biologists, biochemists, pharmacologists, statisticians, biophysicists, bioinformaticians, and software engineers) assists researchers with elucidation of biomarkers of disease progression, elucidation of mechanisms of drug action, improvement of the therapeutic index of cancer drugs, elucidation of novel gene/protein functions, measurement of flux through specific molecular pathways, and many other types of research questions.
Fueled by a passion for improving the accuracy of biological measurements, developing innovative approaches for sample collection and preparation, expanding the limits of measurement technologies, and developing novel approaches for analyzing multi-dimensional data sets, the team has identified and optimized over 50 factors that affect the precision and accuracy of metabolomic data.
Overall, Dr. Lorenzi’s team ensures that experiments are conducted in a technically sound manner to deliver the highest data quality possible and facilitate incisive biological interpretation.
Neil Spooner Ph.D., C.Chem., F.R.S.C.
Founder And Director of Spooner Bioanalytical Solutions
Founder and Director of Spooner Bioanalytical Solutions, a consultancy based in Hertford, UK. Neil is also a Senior Visiting Research Fellow at the School of Life and Medical Sciences, University of Hertfordshire UK, the Senior Editor of Bioanalysis Journal.
Neil Spooner (Ph.D., C.Chem., F.R.S.C.) is the Founder and Director of Spooner Bioanalytical Solutions, a consultancy based in Hertford, UK. Neil is also a Senior Visiting Research Fellow at the School of Life and Medical Sciences, University of Hertfordshire (Hertfordshire, UK), the Senior Editor of Bioanalysis Journal, the Deputy-Chair and Secretary of the Reid Bioanalytical Forum and the Co-Chair of the CPSA Europe meeting.
He has published extensively, with over 60 peer reviewed manuscripts and more than 40 podium presentations at international Conferences and Symposia.
Neils current focus is on working with companies to help them understand the benefits and challenges of microsampling for the generation of high quality bioanalytical data and helping them integrate the technologies into their pre-clinical, clinical and bioanalytical workflows.
Further, he is assisting innovator companies to understand their customers requirements for microsample collection, processing and analysis technologies, enabling them to develop and market devices supported by high quality scientific data.
Prior to this, Neil developed extensive experience in the quantitative bioanalysis of drugs, metabolites and biomarkers in the pharmaceutical industry and contract research organisations in the UK and USA. In over 20 years of industrial practice at GlaxoSmithKline, he has led groups operating in the discovery and regulated arenas of clinical and pre-clinical quantitative bioanalysis and metabolite identification.
Neil has extensive experience of successfully leading inter departmental and cross functional initiatives, including implementation of new technologies and workflows (such as microsampling), outsourcing quantitative bioanalysis, development and implementation of automation approaches and design of new scientific facilities.
Neil is the proud Husband and Father of two teenage daughters. In his spare time, he enjoys travelling with his family, skiing, walking the dog, growing his own produce and making his own wine, cheese and preserves.
Anahita Keyhani, Ph.D.
Senior Director, Scientific Operations Mass Spectrometry at Altasciences
As Senior Director, Scientific Operations Mass Spectrometry, Dr. Keyhani leads a team of over 30 scientists dedicated to Method Development and Innovator Regulated Bioanalysis, clinical and preclinical.
Dr. Keyhani joined Altasciences Clinical Research in May 2015. As Senior Director, Scientific Operations Mass Spectrometry, Dr. Keyhani leads a team of over 30 scientists dedicated to Method Development and Innovator Regulated Bioanalysis, clinical and preclinical. In addition to her role as a scientific and client relationship manager; she actively trains, coaches and mentors scientists from cross-functional departments throughout Altasciences.
Dr. Keyhani received her Bachelor of Science and Master of Science degrees from Ohio State University, with a PhD from McGill University.
Dr. Keyhani has over 20 years of CRO experience in regulated bioanalysis for preclinical and clinical development. Prior to joining Altasciences, her professional career was spent mainly within the bioanalytical group at Charles River Laboratories. She has also worked at Merck in Montreal as a Senior Scientist in Pharmaceutical Research and Development and, during her Masters, participated in research and development projects in the development of pediatric and adult nutritional products at Abbott’s Ross Product division.
In addition to her impressive career path, Dr. Keyhani has authored or co-authored over 15 peer-reviewed publications. She has presented numerous posters and presentations in the bioanalytical domain and actively participates in the Global CRO Council, a forum for CRO leaders to openly discuss bioanalysis and the regulatory challenges unique to the outsourcing industry.
Jennifer Van Eyk, PhD
Director of Advanced Clinical Biosystems Research Institute at Cedars-Sinai's
Widely regarded as a leader in the field of proteomics, Van Eyk joins Cedars-Sinai from Johns Hopkins University School of Medicine, where her laboratory carried out mechanistic research and developed clinical tests to determine whether certain proteins were found in patients' blood samples.